Table 1. Clinical characterization of patients with early-stage idiopathic Parkinson’s disease.
| Patient no. | Sex | Age | Years of disease duration | PANDA cognition | PANDA mood | UPDRS I | UPDRS II | UPDRS III | UPDRS IV | UPDRS total | HY stage | Pharmacological treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P01 | m | 44 | 7 | 24 | 1 | 3 | 9 | 10 | 3 | 25 | 1.5 | LD, RGN, RPN |
| P02 | m | 53 | 8 | 26 | 0 | 2 | 9 | 13 | 1 | 25 | 1.5 | AMN, LD, SGN, PPX |
| P03 | m | 45 | 5 | 30 | 2 | 0 | 14 | 11 | 2 | 27 | 1.0 | RGN |
| P04 | m | 49 | 1 | 15 | 2 | 1 | 2 | 5 | 2 | 10 | 1.0 | PPX, RGN |
| P05 | m | 44 | 4 | 26 | 0 | 0 | 5 | 12 | 0 | 17 | 1.0 | AMN, PPX, RGN |
| P06 | m | 45 | 3 | 14 | 1 | 1 | 6 | 12 | 1 | 20 | 1.0 | CD, EC, LD, PPX, RGN |
| P07 | f | 53 | 5 | 30 | 0 | 0 | 5 | 14 | 6 | 25 | 1.0 | CD, LD, RGN, RPN |
| P08 | m | 42 | 5 | 27 | 3 | 1 | 13 | 21 | 4 | 39 | 2.0 | CD, LD, RGN |
| P09 | m | 43 | 4 | 28 | 4 | 1 | 11 | 12 | 1 | 25 | 1.5 | CD, AMN, LD, SGN, |
| P10 | f | 54 | 2 | 24 | 3 | 3 | 8 | 15 | 0 | 26 | 2.0 | AMN, PPX, SGN |
| P11 | f | 44 | 6 | 24 | 3 | 0 | 4 | 22 | 1 | 27 | 1.0 | CD, LD, BP |
| P12 | m | 57 | 5 | 29 | 3 | 2 | 4 | 15 | 0 | 21 | 1.0 | LD, PPX, RGN |
| P13 | f | 59 | 3 | 26 | 1 | 0 | 2 | 11 | 0 | 13 | 1.0 | CD, LD, RGN |
| M | 48.62 | 4.46 | 24.85 | 1.77 | 1.08 | 7.08 | 13.31 | 1.62 | 23.08 | 1.27 | ||
| ± SD | ± 5.85 | ± 1.94 | ± 5.05 | ± 1.36 | ± 1.11 | ± 3.95 | ± 4.44 | ± 1.81 | ± 7.25 | ± 0.39 |
Clinical test data were collected after at least 12 hours withdrawal of pharmacological antiparkinsonian treatment.
AMN: amantadine, BP: biperiden, CD: carbidopa, EC: entacapone, f: female, LD: L-dopa, M: mean, m: male, PANDA: Parkinson Neuropsychometric Dementia Assessment, PPX: pramipexole, RGN: rasagiline, RPN: ropinirole, SD: standard deviation, SGN: selegiline, UPDRS: Unified Parkinson’s Disease Rating Scale, HY stage: Hoehn & Yahr stage.